NVO: 6-K company filing

6-K 1 f6k_110526.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 5, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf .. Please find below a statement of such trading in shares issued by Novo Nordisk. Page 2 of 3 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Martin Holst Lange 2 Reason for the notification a) Position/status Executive Vice President, R&D and Chief Scientific Officer (CSO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Sha